Similarly, the combination of an EGFR-CAR-modified NK92 cell line therapy with the oncolytic herpes simplex virus 1 (oHSV-1) is a promising strategy for the treatment of EGFR-positive breast cancer that has metastasized to the brain (Chen et al., 2016). Here, EGFR is linked to breast carcinoma.